Tony Butler
Stock Analyst at Rodman & Renshaw
(0.56)
# 4,066
Out of 5,182 analysts
88
Total ratings
27.38%
Success rate
-22.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tony Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Initiates: Buy | $25 | $4.76 | +425.21% | 2 | Dec 20, 2024 | |
| HURA TuHURA Biosciences | Initiates: Buy | $11 | $2.13 | +416.43% | 1 | Dec 19, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $18 | $1.53 | +1,076.47% | 4 | Sep 26, 2024 | |
| IPSC Century Therapeutics | Reiterates: Buy | $16 | $2.20 | +627.27% | 5 | Aug 10, 2023 | |
| FATE Fate Therapeutics | Reiterates: Buy | $10 | $1.30 | +669.23% | 4 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Buy | $75 | $52.06 | +44.06% | 8 | Aug 8, 2023 | |
| GTBP GT Biopharma | Reiterates: Hold | $60 | $0.28 | +21,108.91% | 5 | Aug 7, 2023 | |
| CGEN Compugen | Reiterates: Buy | $13 | $2.73 | +376.19% | 6 | Aug 7, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $50 | $4.69 | +966.10% | 5 | Aug 3, 2023 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $15 | $2.19 | +584.93% | 8 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1,250 | $4.30 | +28,969.77% | 6 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.70 | +782.35% | 1 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.04 | +228.95% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $0.58 | +2,848.83% | 2 | Jul 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8.3 → $166 | $3.89 | +4,167.35% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $2.57 | +2,234.63% | 4 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.53 | +15,586.27% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.78 | +115.83% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $360 | $0.40 | +89,900.00% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $5 → $2 | $2.26 | -11.65% | 6 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.72 | +1,985.36% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $10 | $1.42 | +604.23% | 2 | Feb 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.84 | +715.22% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $110 | $13.20 | +733.33% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $960 | $9.25 | +10,278.38% | 1 | Mar 2, 2020 |
Atara Biotherapeutics
Dec 20, 2024
Initiates: Buy
Price Target: $25
Current: $4.76
Upside: +425.21%
TuHURA Biosciences
Dec 19, 2024
Initiates: Buy
Price Target: $11
Current: $2.13
Upside: +416.43%
Biomea Fusion
Sep 26, 2024
Upgrades: Buy
Price Target: $18
Current: $1.53
Upside: +1,076.47%
Century Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $16
Current: $2.20
Upside: +627.27%
Fate Therapeutics
Aug 9, 2023
Reiterates: Buy
Price Target: $10
Current: $1.30
Upside: +669.23%
CRISPR Therapeutics AG
Aug 8, 2023
Reiterates: Buy
Price Target: $75
Current: $52.06
Upside: +44.06%
GT Biopharma
Aug 7, 2023
Reiterates: Hold
Price Target: $60
Current: $0.28
Upside: +21,108.91%
Compugen
Aug 7, 2023
Reiterates: Buy
Price Target: $13
Current: $2.73
Upside: +376.19%
Bicycle Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $50
Current: $4.69
Upside: +966.10%
Allogene Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $15
Current: $2.19
Upside: +584.93%
Aug 2, 2023
Reiterates: Buy
Price Target: $1,250
Current: $4.30
Upside: +28,969.77%
Jul 31, 2023
Initiates: Buy
Price Target: $15
Current: $1.70
Upside: +782.35%
Jul 12, 2023
Reiterates: Buy
Price Target: $10
Current: $3.04
Upside: +228.95%
Jul 7, 2023
Reiterates: Buy
Price Target: $17
Current: $0.58
Upside: +2,848.83%
Jul 3, 2023
Reiterates: Buy
Price Target: $8.3 → $166
Current: $3.89
Upside: +4,167.35%
Jun 7, 2023
Reiterates: Buy
Price Target: $60
Current: $2.57
Upside: +2,234.63%
Jun 5, 2023
Reiterates: Buy
Price Target: $240
Current: $1.53
Upside: +15,586.27%
Jun 1, 2023
Assumes: Buy
Price Target: $6
Current: $2.78
Upside: +115.83%
Jun 1, 2023
Assumes: Buy
Price Target: $360
Current: $0.40
Upside: +89,900.00%
May 30, 2023
Maintains: Hold
Price Target: $5 → $2
Current: $2.26
Upside: -11.65%
Jan 5, 2023
Initiates: Buy
Price Target: $15
Current: $0.72
Upside: +1,985.36%
Feb 17, 2022
Downgrades: Neutral
Price Target: $30 → $10
Current: $1.42
Upside: +604.23%
Nov 19, 2021
Initiates: Buy
Price Target: $15
Current: $1.84
Upside: +715.22%
Jun 28, 2021
Maintains: Buy
Price Target: $80 → $110
Current: $13.20
Upside: +733.33%
Mar 2, 2020
Initiates: Buy
Price Target: $960
Current: $9.25
Upside: +10,278.38%